Ad hoc releases are announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
View Featured news and Pulse updates.
Header
Newsroom
Showing 1851 results
June 2016
-
Press release
Novartis combination therapy Tafinlar® + Mekinist® demonstrates overall survival benefit at three-year follow-up in patients with advanced melanoma
Study is longest Ph III survival follow-up to date of BRAF V600E/K mutation-positive melanoma patients who received a targeted combination therapy Latest data show an estimated 44% of… -
Press release
Novartis pivotal data for Tafinlar® + Mekinist® demonstrated a 63 percent overall response rate in treating rare form of lung cancer
The median Duration of Response for BRAF V600E-mutant NSCLC patients treated with Tafinlar® + Mekinist® combination therapy was 9 months Efficacy analyses also presented for INC280 (… -
Story Access to Healthcare
Fighting pneumonia, the biggest killer of young children
Pneumonia causes around 2 million child deaths per year globally and the burden is especially heavy in a country like Bangladesh, where a third of the population is aged 14 or below.
-
Story Patient Perspectives
Lung Cancer: To test or not to test
For patients with lung cancer, biomarker testing may be an option.
-
Press release
Novartis data show more than 50 percent of eligible Ph+ CML patients maintain Treatment-free Remission (TFR) after stopping Tasigna®
In ENESTfreedom, 51.6% of eligible first-line Tasigna patients maintained TFR for 48 weeks after stopping treatment; study did not meet its statistical primary endpoint, specifically the >… -
Story Patient Perspectives
Your Genes, Your Melanoma
Learn about the role of precision oncology in advanced melanoma treatment.
-
In The News
Novartis Access hosts second stakeholder dialogue
The second stakeholder dialogue shared first learnings from the Kenya launch, and to continue the discussion on how to address the burden of NCDs in lower-income countries. -
Press release
Novartis drug Afinitor® receives EU approval to treat certain types of advanced gastrointestinal (GI) and lung neuroendocrine tumors (NET)
Afinitor fills critical need in EU as first approved therapy for advanced, progressive, nonfunctional lung NET and first oral therapy for this type of GI NET Nonfunctional GI and lung NET are…
May 2016
-
Press release
Novartis highlights its strong foundation for long-term, sustainable growth at the third Meet Novartis Management event
Outlines actions underway to accelerate launch of Entresto®, including further expansion of US primary care field force, and reinforce strong uptake of Cosentyx® Highlights… -
Press release
Sandoz' biosimilar rituximab regulatory submission accepted by European Medicines Agency
Sandoz advances biosimilar portfolio with sixth major biosimilar file acceptance in less than one year Sandoz is seeking approval for all indications included in the reference product's label… -
Press release
Novartis' Entresto® given strong Class I recommendation in both US and EU heart failure guidelines, less than a year after regulatory approvals
US guidelines now recommend Entresto as standard of care for HFrEF as an alternative to ACEs or ARBs; call for doctors to switch patients with mild to moderate symptoms to Entresto[1] Updated… -
Story From Our Labs
Building brain organoids to shed light on disease
Three-dimensional clusters of human neurons could allow scientists to watch neurological diseases develop in the lab.